Last C$0.21 CAD
Change Today -0.015 / -6.67%
Volume 113.3K
TST On Other Exchanges
TST is not on other exchanges.
As of 3:34 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

telesta therapeutics inc (TST) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/14 - C$0.44
52 Week Low
06/2/14 - C$0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

telesta therapeutics inc (TST) Related Businessweek News

No Related Businessweek News Found

telesta therapeutics inc (TST) Details

Telesta Therapeutics Inc., a late clinical stage biopharmaceutical company, engages in the development, manufacture, marketing, and licensing/acquisition of proprietary and therapeutic products for the human health markets worldwide. Its lead product, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) suspension, is a complex biologic immunotherapy/immunomodulator designed for the treatment of non-muscle-invasive bladder cancer in humans, which has completed Phase III clinical trials. The company was formerly known as Bioniche Life Sciences Inc. and changed its name to Telesta Therapeutics Inc. in November 2014. Telesta Therapeutics Inc. was founded in 1979 and is headquartered in Belleville, Canada.

Founded in 1979

telesta therapeutics inc (TST) Top Compensated Officers

Chief Executive Officer, Chief Scientist Offi...
Total Annual Compensation: C$256.3K
Founder, Chairman Emeritus and Board Observer
Total Annual Compensation: C$132.6K
Chief Financial Officer
Total Annual Compensation: C$225.0K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: C$130.0K
Vice President of Manufacturing Operations
Total Annual Compensation: C$201.6K
Compensation as of Fiscal Year 2014.

telesta therapeutics inc (TST) Key Developments

Telesta Therapeutics Announces Clinical Updates

Telesta Therapeutics Inc. affirmed that they remain on track with their internal objective of filing a Biologics License Application (BLA) for marketing approval with the US Food and Drug Administration (FDA) for MCNA 1 prior to March 31, 2015. Two recent key accomplishments include the completion of both a pre-BLA meeting with the US FDA and a mock-audit of Telesta's MCNA manufacturing facility. As the result of the pre-BLA meeting, Telesta received written answers and verbal feedback to a number of clinical, manufacturing and regulatory items related to the filing of their BLA while the manufacturing "mock-audit" saw a third party firm complete a detailed and exhaustive review intended to simulate the type of audit that Telesta is expected to be subject to, by the FDA, during the course of a BLA review process. In parallel, Telesta expects to conclude their third party assessment of the market opportunity for MCNA, in the United States, in the weeks to come. This market assessment, where qualitative and quantitative primary market research was conducted with payers (managed care organizations/decision makers both from the private and public sector) and urologists (community urologists and key opinion leaders), will address issues such as market size, pricing/pricing strategy and market access context/reimbursement potential for MCNA. These data will be key in assisting Telesta to make informed decisions concerning overall market potential and optimal licensing/partnering and/or commercial development strategy.

Telesta Therapeutics Inc. Announces Resignation of Greg Gubitz as Director

Telesta Therapeutics Inc. announced that its Board of Directors has accepted the resignation of Mr. Greg Gubitz as a Director of the Company.

Telesta Therapeutics Inc. has Changed its Ticker to TST from BNC

Telesta Therapeutics Inc. changed its The Toronto Stock Exchange stock ticker symbol to TST from BNC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TST:CN C$0.21 CAD -0.015

TST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TST.
View Industry Companies

Industry Analysis


Industry Average

Valuation TST Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 70.6x
Price/Book 5.8x
Price/Cash Flow 3.9x
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TELESTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at